Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 12;25(4):2208.
doi: 10.3390/ijms25042208.

Bruton's Tyrosine Kinase Inhibitors: Recent Updates

Amneh Fares  1   2 , Carlos Carracedo Uribe  1   2 , Diana Martinez  1   2 , Tauseef Rehman  1   2 , Carlos Silva Rondon  2 , Jose Sandoval-Sus  2
Affiliations
Review

Bruton's Tyrosine Kinase Inhibitors: Recent Updates

Amneh Fares et al. Int J Mol Sci. .

Abstract

Bruton's tyrosine kinase (BTK) inhibitors have revolutionized the landscape for the treatment of hematological malignancies, solid tumors, and, recently, autoimmune disorders. The BTK receptor is expressed in several hematopoietic cells such as macrophages, neutrophils, mast cells, and osteoclasts. Similarly, the BTK receptor is involved in signaling pathways such as chemokine receptor signaling, Toll-like receptor signaling, and Fc receptor signaling. Due to their unique mechanism, these agents provide a diverse utility in a variety of disease states not limited to the field of malignant hematology and are generally well-tolerated.

Keywords: Bruton’s kinase inhibitors; acalabrutinib; autoimmune disorders; hematologic malignancies; ibrutinib; pirtobrutinib; zanubrutinib.

PubMed Disclaimer

Conflict of interest statement

Jose Sandoval-Sus is a speaker for Seagen, has been a consultant for Massive Bio, and has been on the advisory board for Genmab, AbbVie, Genentech and ADC Therapeutics.

Figures

Figure 1
Figure 1
Overview of BTK signaling pathway highlighting the downstream signaling cascade and intracellular signaling pathway blockade [3].
See this image and copyright information in PMC

References

    1. Tasso B., Spallarossa A., Russo E., Brullo C. The Development of BTK Inhibitors: A Five-Year Update. Molecules. 2021;26:7411. doi: 10.3390/molecules26237411. - DOI - PMC - PubMed
    1. Burger J.A., Wiestner A. Targeting B cell receptor signalling in cancer: Preclinical and clinical advances. Nat. Rev. Cancer. 2018;18:148–167. doi: 10.1038/nrc.2017.121. - DOI - PubMed
    1. Alu A., Lei H., Han X., Wei Y., Wei X. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: Mechanisms and clinical studies. J. Hematol. Oncol. 2022;15:138. doi: 10.1186/s13045-022-01353-w. - DOI - PMC - PubMed
    1. Burger J.A. Bruton Tyrosine Kinase Inhibitors: Present and Future. Cancer J. 2019;25:386–393. doi: 10.1097/PPO.0000000000000412. - DOI - PMC - PubMed
    1. Mano H. Tec family of protein-tyrosine kinases: An overview of their structure and function. Cytokine Growth Factor Rev. 1999;10:267–280. doi: 10.1016/S1359-6101(99)00019-2. - DOI - PubMed

MeSH terms

Substances